Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 13Sarcoma 4Gastrointestinal 2Lymphoid 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 10184Triple Negative Breast Neoplasms 1046Neoplasms 574Ovarian Neoplasms 564Neoplasm Metastasis 515Colorectal Neoplasms 473Carcinoma, Non-Small-Cell Lung 468Prostatic Neoplasms 440Lung Neoplasms 433Pancreatic Neoplasms 312Melanoma 299Stomach Neoplasms 295Breast Neoplasms, Male 257Motor Activity 252Colonic Neoplasms 238Uterine Cervical Neoplasms 227Endometrial Neoplasms 223Head and Neck Neoplasms 218Carcinoma, Intraductal, Noninfiltrating 217Carcinoma, Renal Cell 192Squamous Cell Carcinoma of Head and Neck 181Sarcoma 177Urinary Bladder Neoplasms 159Esophageal Neoplasms 155Brain Neoplasms 155Breast Carcinoma In Situ 154Lymphedema 148Fatigue 136Carcinoma, Ovarian Epithelial 134Small Cell Lung Carcinoma 130

Interventions

palbociclib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Endometrioid × Breast × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡